Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
EGRX
$50.67
Eagle Pharmaceuticals
($.06)
(.12%)
EGRX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus: ($1.42)
Revenue: $50.07 Mil
Monday
Feb 1
6:45 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Monday, November 02, 2020
Eagle Pharmaceuticals Reports Third Quarter 2020 Results
What do you expect when EGRX reports earnings?
Beat
Meet
Miss
Where is EGRX's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
-
-
-
-
Support
-
-
-
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
Peers
InterCept
Regeneron Pharmaceuticals
Vertex Pharmaceuticals
BioMarin Pharmaceutical
Zoetis
Bristol-Myers Squibb
Pfizer
Merck & Co.
Eli Lilly
Johnson & Johnson
Expectations
›
Eagle Pharmaceuticals
